Bartie Wendy Short, the EVP of $BMY, sold 378 shares of the company on 08-02-2025 for an estimated $16,718. We received data on the trade from a recent SEC filing. This was a sale of approximately 6.9% of their shares of this class of stock. Following this trade, they now own 5,066 shares of this class of $BMY stock.
$BMY Insider Trading Activity
$BMY insiders have traded $BMY stock on the open market 5 times in the past 6 months. Of those trades, 3 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $BMY stock by insiders over the last 6 months:
- SAMIT HIRAWAT (EVP,Chief Med.Offr.,Drug Dev.) has made 2 purchases buying 6,073 shares for an estimated $302,214 and 0 sales.
- CHRISTOPHER S. BOERNER (Chief Executive Officer) purchased 2,000 shares for an estimated $110,096
- BARTIE WENDY SHORT (EVP, Corporate Affairs) sold 378 shares for an estimated $16,718
- BENJAMIN HICKEY (President, RayzeBio Org.) sold 97 shares for an estimated $3,701
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$BMY Hedge Fund Activity
We have seen 983 institutional investors add shares of $BMY stock to their portfolio, and 1,307 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL INTERNATIONAL INVESTORS added 20,599,149 shares (+44.9%) to their portfolio in Q1 2025, for an estimated $1,256,342,097
- WELLINGTON MANAGEMENT GROUP LLP added 17,750,938 shares (+297.0%) to their portfolio in Q1 2025, for an estimated $1,082,629,708
- JPMORGAN CHASE & CO added 12,029,292 shares (+12.5%) to their portfolio in Q1 2025, for an estimated $733,666,519
- GQG PARTNERS LLC added 11,970,598 shares (+22647.6%) to their portfolio in Q1 2025, for an estimated $730,086,772
- FMR LLC removed 9,489,393 shares (-30.5%) from their portfolio in Q1 2025, for an estimated $578,758,079
- MILLENNIUM MANAGEMENT LLC removed 7,928,263 shares (-93.5%) from their portfolio in Q1 2025, for an estimated $483,544,760
- BANK OF NEW YORK MELLON CORP removed 6,003,704 shares (-22.3%) from their portfolio in Q2 2025, for an estimated $277,911,458
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$BMY Congressional Stock Trading
Members of Congress have traded $BMY stock 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $BMY stock by members of Congress over the last 6 months:
- REPRESENTATIVE VIRGINIA FOXX sold up to $15,000 on 06/24.
- REPRESENTATIVE JEFFERSON SHREVE sold up to $50,000 on 05/12.
- SENATOR TOMMY TUBERVILLE sold up to $15,000 on 04/15.
- REPRESENTATIVE JULIE JOHNSON sold up to $15,000 on 04/01.
- REPRESENTATIVE GREG LANDSMAN sold up to $15,000 on 03/27.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$BMY Analyst Ratings
Wall Street analysts have issued reports on $BMY in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Jefferies issued a "Buy" rating on 04/23/2025
- Piper Sandler issued a "Overweight" rating on 04/22/2025
To track analyst ratings and price targets for $BMY, check out Quiver Quantitative's $BMY forecast page.
$BMY Price Targets
Multiple analysts have issued price targets for $BMY recently. We have seen 8 analysts offer price targets for $BMY in the last 6 months, with a median target of $54.5.
Here are some recent targets:
- Andrew Baum from Citigroup set a target price of $47.0 on 08/01/2025
- Terence Flynn from Morgan Stanley set a target price of $34.0 on 07/10/2025
- Mohit Bansal from Wells Fargo set a target price of $53.0 on 04/28/2025
- Carter Gould from Cantor Fitzgerald set a target price of $55.0 on 04/23/2025
- Akash Tewari from Jefferies set a target price of $68.0 on 04/23/2025
- David Amsellem from Piper Sandler set a target price of $65.0 on 04/22/2025
- Trung Huynh from UBS set a target price of $54.0 on 04/11/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
